A prospective trial of adjuvant therapy for high-risk uveal melanoma: Assessing 5-year survival outcomes

Source: MDLinx, September 2019

Because survival after diagnosis of uveal melanoma metastasis is poor, researchers conducted an adjuvant trial of sequential, low-dose dacarbazine (DTIC) and interferon-alpha-2b (IFN-??2b) in patients with cytogenetic high-risk uveal melanoma. Adjuvant treatment with low-dose DTIC and IFN-??2b following primary therapy was offered to patients diagnosed with iris, ciliary body, or choroidal melanoma with high-risk tumor cytogenetics (monosomy 3). Data reported that the 5-year metastasis-free survival was 64% ± 9% for treated and 33% ± 10% for observed patients and the 5-year overall survival rate was 66% ± 9% for treated and 37% ± 10% for observed patients. Survival between treated and observed patients was no longer significant when adjusted for differences in age, tumor size and initial treatment. Differences in the features of the baseline tumor between patients treated and observed may affect the interpretation of outcomes.

Read the original full article